Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.

Original reporting
Published Nov 16, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$OMER
Bearish
high confidence
Mentioned
$OMER
Relevance
8/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$OMERBearishMed
01

Why it matters

The immediate tradable signal is the divergence between adjusted profitability and GAAP loss, with the after-hours selloff indicating investors are penalizing accounting volatility and/or balance-sheet risk even amid revenue growth.

02

Market read

Traders should focus on the after-hours reaction and the stated driver of the GAAP loss, since it can dominate near-term sentiment despite adjusted beat and positive cash flow.

03

What to watch

Gross-to-net adjustment rose to 14.0% from 11.5%, and 340B participation increased; both could affect future margins and investor confidence beyond the headline GAAP loss.

Relevance 8/10Novelty 8/10Timing: after-hours reaction following Q3 results release

Background

Omeros’ Q3 included YARTEMLEA growth and positive operating cash flow, but GAAP results deteriorated due to a large non-cash derivative loss tied to convertible notes.

Company-level read

Ticker impact

$OMERBearishHigh confidence
Context

Omeros reported Q3 revenue of $41.8M and adjusted EPS of $0.06, but shares fell 10% after-hours on a widened GAAP net loss tied to convertible-note derivatives.

Expected impact

Likely continued pressure or choppy trading as investors weigh adjusted outperformance against the widened GAAP loss and derivative-driven volatility.

Evidence & confidence

The article directly links the after-hours 10% drop to the widened GAAP net loss and specifies the non-cash $62.0M derivative mark-to-market driver.

Market effects

Highlights how biotech investors may discount adjusted beats when GAAP losses widen due to non-cash derivative accounting, potentially increasing sensitivity to balance-sheet/convertible structures.

Limited, as the catalyst is company-specific and US-listed trading.

Moderate for European regulatory sentiment, since the article references a prior EMA negative opinion on narsoplimab.

Counterpoint

The GAAP loss is largely non-cash derivative mark-to-market, while operating cash flow was positive and YARTEMLEA revenue grew sequentially, which may support a rebound if investors refocus on cash generation.

Key entities

  • Omeros Corporation

    NASDAQ-listed biotech whose Q3 beat was offset by a widened GAAP net loss and a 10% after-hours share drop.

  • YARTEMLEA

    Omeros’ approved stem cell transplant-associated thrombotic microangiopathy treatment; generated $41.8M gross revenue in Q3.

  • European Medicines Agency (CHMP)

    Issued a negative opinion on Omeros’ narsoplimab marketing authorization application in TA-TMA after re-examination.

Related articles

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

$OMERMed

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

$OMERMed

Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q